Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation
- 428 Downloads
Major depressive disorder (MDD) is a highly prevalent illness that affects large populations across the world, and increasing evidence suggests that neuroinflammation and levels of brain-derived neurotrophic factor (BDNF) are closely related to depression. Dihydromyricetin (DHM) is a kind of flavonoid natural product that has been reported to display multiple pharmacological effects, including anti-inflammatory and anti-oxidative properties, and these may contribute to ameliorate MDD.
This study investigated the effect of DHM on depression-related phenotypes in various experimental animal models.
The antidepressant-like effect of DHM was validated via depression-related behavioral tests in naïve male C57BL/6 mice, as well as in the acute lipopolysaccharide-induced mouse model of depression. The chronic unpredicted mild stress (CUMS) mouse model of depression was also used to assess the rapid antidepressant-like effect of DHM by tail suspension test (TST), forced swimming test (FST), locomotor activity, and sucrose preference test (SPT). The expression of BDNF and inflammatory factors were determined through Western blotting and enzyme-linked immunosorbent assay, respectively.
DHM reduced immobility time in the TST and FST both in mice and the acute LPS-induced mouse model of depression. Seven days of DHM treatment ameliorated depression-related behaviors induced by CUMS, whereas similar treatment with the typical antidepressant venlafaxine did not. DHM activated the ERK1/2-CREB pathway and increased glycogen synthase kinase-3 beta (GSK-3β) phosphorylation at ser-9, with upregulation of BDNF expression, in both hippocampal tissues and cultured hippocampal cells.
The present data indicate that DHM exerts a more rapid antidepressant-like effect than does a typical antidepressant, in association with enhancement of BDNF expression and inhibition of neuroinflammation.
KeywordsDihydromyricetin Antidepressant activity Brain-derived neurotrophic factor ERK1/2 Glycogen synthase kinase-3β
This work was supported by funds from the National Science Foundation of China (81130023, 30825042). Support provided from the Priority Academic Program Development of Jiangsu Higher Education Institutes (PAPD) and the Jiangsu key laboratory grant (BM2013003) is also appreciated.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- BoJiang, LuSong, Cheng-NiuWang, WeiZhang, ChaoHuang, Li-JuanTong (2016) Antidepressant-like effects of GM1 ganglioside involving the BDNF signaling cascade in mice. International Journal of Neuropsychopharmacology 19: pyw046Google Scholar
- Bui C, Barter MJ, Scott JL, Xu Y, Galler M, Reynard LN, Rowan AD, Young DA (2012) cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis. Faseb Journal Official Publication of the Federation of American Societies for. Exp Biol 26:3000–3011Google Scholar
- Chen S, Zhao X, Wan J, Ran L, Qin Y, Wang X, Gao Y, Shu F, Zhang Y, Liu P, Zhang Q, Zhu J, Mi M (2015) Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: a randomized controlled trial. Pharmacol Res 99:74–81CrossRefPubMedGoogle Scholar
- Cheng J, Salton SR (2013) The role of neurotrophins in major depressive disorder. Transl Neurosci 4:46–58Google Scholar
- Harrisberger F, Smieskova R, Schmidt A, Lenz C, Walter A, Wittfeld K, Grabe HJ, Lang UE, Fusar-Poli P, Borgwardt S (2015) BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev 55:107–118CrossRefPubMedGoogle Scholar
- Hughes MM, Connor TJ, Harkin A (2016) Stress-related immune markers in depression: implications for treatment. Int J NeuropsychopharmacolGoogle Scholar
- Kaufmann FN, Costa AP, Ghisleni G, Diaz AP, Rodrigues AL, Peluffo H, Kaster MP (2017) NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings. Brain Behav ImmunGoogle Scholar
- Vogelzangs N, Beekman AT, van Reedt Dortland AK, Schoevers RA, Giltay EJ, de Jonge P, Penninx BW (2014) Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacol : Off Publ Am Coll Neuropsychopharmacol 39:1624–1634CrossRefGoogle Scholar
- Xu LZ, Xu DF, Han Y, Liu LJ, Sun CY, Deng JH, Zhang RX, Yuan M, Zhang SZ, Li ZM, Xu Y, Li JS, Xie SH, Li SX, Zhang HY, Lu L (2016) BDNF-GSK-3beta-beta-catenin pathway in the mPFC is involved in antidepressant-like effects of Morinda officinalis oligosaccharides in rats. Int J NeuropsychopharmacolGoogle Scholar
- Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (2014) Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 18Google Scholar